MVF – Macquarie rates the stock as Outperform
The Outperform rating and target price of $1.20 are retained.
Read More
The Monash IVF Group has a world class internal quality assurance program and competency review system which supplements the reviews performed by the reproductive treatment authority committee (RTAC). We quantitatively and qualitatively monitor and control every aspect of the IVF process to ensure our specialists, nurses and scientists consistently provide the highest quality care and our technology performs at the highest level. These comprehensive measures ensure all patients have the best possible opportunity of achieving their dream of having a family.
The Monash IVF Group pride themselves on a multi-disciplinary team approach consisting of Fertility Specialists, Sonologists, Fertility Nurses, Scientists, Counsellors and Patient Coordinators who work closely with their patients to achieve the best possible chance of success.
The Outperform rating and target price of $1.20 are retained.
Read More
The broker retains an Add rating and lowers forecasts in-line with the recent trading update. The target price is reduced to $1.25 from $1.29.
Read More
The target price lifts to $1.15 from $1.10. The Outperform rating is maintained.
Read More
At the AGM, Monash IVF noted a strong rebound from July to October. This was indicated by stimulated cycles growing by 23.1%, international up 16.2% and the Ultrasound business up 10.7%.
Read More
FY20 guidance has been withdrawn. Morgans believes it appropriate to revise forecasts and adjust dividend expectations, as cash conservation is paramount.
Read More
Morgans downgrades Monash IVF to Hold from Add to reflect recent share price strength.
Read More
The flagging housing market and sagging consumer sentiment ahead of the federal and NSW elections have affected the performance of an unlikely ASX-listed exponent - the assisted reproduction outfit Virtus Health (VRT, $3.98).
Read More